Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 9:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: InFuSE Clear all
Withdrawn Phase 4 Interventional

Adductor Canal Catheter vs Local Infiltration of Analgesia for Total Knee Arthroplasty

NCT02603900
View directory record Official record
Conditions
Acute Pain, Regional Anesthesia Morbidity
Interventions
ropivacaine, bupivacaine, Sham Adductor Canal Catheter, Adductor Canal Catheter
Drug · Device
Lead sponsor
Thomas Jefferson University
Other
Eligibility
40 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 11, 2026, 9:10 PM EDT
Not listed Not applicable Interventional

An Extension Study MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue

NCT04240639
View directory record Official record
Conditions
Neoplasms of the Prostate
Interventions
AuroShell particle infusion
Device
Lead sponsor
Nanospectra Biosciences, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Sep 11, 2026, 9:10 PM EDT
Completed Phase 1 Interventional

Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression

NCT03887741
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Plasmapheresis, Plasma infusion
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Sep 11, 2026, 9:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing Through-the-Needle With Suture-Method Catheter Designs for Popliteal Nerve Blocks

NCT03442036
View directory record Official record
Conditions
Regional Anesthesia, Sciatic Nerve Block
Interventions
Suture-Method Technique, Through-the-Needle Technique
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Sep 11, 2026, 9:10 PM EDT
Completed Phase 1 Interventional Results available

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

NCT03049449
View directory record Official record
Conditions
Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Extranodal NK-T-Cell, Lymphoma, T-Cell, Peripheral
Interventions
Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 73 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Sep 11, 2026, 9:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Approved Contact Lenses

NCT07174596
View directory record Official record
Conditions
Visual Acuity
Interventions
B+L Infuse spherical soft contact lenses, J&J ACUVUE OASYS 1-Day spherical soft contact lenses
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
4
States / cities
Roswell, Georgia • New Bremen, Ohio • Salem, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 11, 2026, 9:10 PM EDT
Terminated Phase 4 Interventional Results available

A Study Comparing Continuous Sciatic Nerve Block to Single Shot Sciatic Nerve Block

NCT01615939
View directory record Official record
Conditions
Fracture of Foot
Interventions
Bupivacaine, Ropivacaine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Sep 11, 2026, 9:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant

NCT00886262
View directory record Official record
Conditions
Liver Failure
Interventions
Vasopressin, Normal saline placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 11, 2026, 9:10 PM EDT
Completed Phase 2 Interventional Results available

Prevention of Acute Kidney Injury in Cardiac Surgery Patients

NCT00921518
View directory record Official record
Conditions
Kidney Injury
Interventions
0.9% Sodium Chloride (Placebo), Sodium Bicarbonate
Drug
Lead sponsor
Community Medical Center, Scranton, PA
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Sep 11, 2026, 9:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

NCT01483690
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia, Precursor T-Cell Lymphoblastic Leukemia
Interventions
Decitabine, Vorinostat, Vincristine, Dexamethasone, Mitoxantrone, Pegaspargase, Methotrexate
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
25
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 11, 2026, 9:10 PM EDT
Active, not recruiting No phase listed Observational

A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders

NCT06126341
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM, Hospital Anxiety and Depression Scale, Duke-UNC Functional Social Support Questionnaire, Distress Thermometer, FACT-BMT, Psychosocial Assessments of Candidates for Transplantation
Other · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
8
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 11, 2026, 9:10 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)

NCT01116102
View directory record Official record
Conditions
Dehydration
Interventions
Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2011 · Synced Sep 11, 2026, 9:10 PM EDT
Terminated Not applicable Interventional

Adductor Canal Block (ACB) vs Femoral Nerve Block (FNB) in Revision Total Knee Arthroplasty

NCT03697538
View directory record Official record
Conditions
Revision Total Knee Arthroplasty
Interventions
Nerve Block for pain control post-revision total knee arthroplasty
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Sep 11, 2026, 9:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase

NCT00807885
View directory record Official record
Conditions
Dehydration
Interventions
hylenex-facilitated subcutaneous Lactated Ringer's infusion
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Lincoln, Nebraska • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 25, 2011 · Synced Sep 11, 2026, 9:10 PM EDT
Not listed Not applicable Interventional

SPIRA™-A 3D and HCT/p DBM vs. Medtronic Divergent™-L/Perimeter™ and Recombinant BMP-2

NCT04566874
View directory record Official record
Conditions
Degenerative Disc Disease, Spinal Stenosis, Spondylolisthesis, Scoliosis
Interventions
ALIF
Device
Lead sponsor
Camber Spine Technologies
Industry
Eligibility
22 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2020 · Synced Sep 11, 2026, 9:10 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Refitting Satisfied INFUSE One-Day Multifocal Wearers to DAILIES TOTAL1 Multifocal Contact Lenses

NCT07638943
View directory record Official record
Conditions
Contact Lens Comfort and Successful Refitting, Presbyopia
Interventions
DAILIES TOTAL1 Multifocal (delefilcon A)
Device
Lead sponsor
Gordon Schanzlin New Vision
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 11, 2026, 9:10 PM EDT
Completed Not applicable Interventional Results available

Clinical Performance of Two Commercial, Daily Disposable Contact Lenses

NCT05010512
View directory record Official record
Conditions
Refractive Errors, Ametropia, Myopia
Interventions
Delefilcon A contact lenses, Kalifilcon A contact lenses
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
8
States / cities
Orlando, Florida • Tallahassee, Florida • Bloomington, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 11, 2026, 9:10 PM EDT
Completed Phase 2 Interventional Results available

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

NCT02441803
View directory record Official record
Conditions
Leukemia
Interventions
Busulfan, Fludarabine, Clofarabine, Total Body Irradiation (TBI), Thymoglobulin, Stem Cell Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Decitabine, Cytarabine, Idarubicin
Drug · Radiation · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 11, 2026, 9:10 PM EDT
Terminated Phase 3 Interventional Results available

INFUSE®Bone Graft in Transforaminal Lumbar Interbody Fusion for Degenerative Disease of Lumbosacral Spine

NCT01415908
View directory record Official record
Conditions
Lumbar Spine Degeneration
Interventions
INFUSE Bone Graft, Iliac Crest Bone Graft
Device · Other
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Mesa, Arizona • Los Angeles, California • Gulf Breeze, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Sep 11, 2026, 9:10 PM EDT
Terminated Phase 2 Interventional Results available

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

NCT01116232
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, rituximab, sirolimus, tacrolimus, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, management of therapy complications, peripheral blood stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 11, 2026, 9:10 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Tibial Delayed Healing Pivotal Clinical Trial

NCT01016067
View directory record Official record
Conditions
Tibial Delayed Healing
Interventions
INFUSE/MASTERGRAFT, Autograft bone
Device · Procedure
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
21 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
16
States / cities
Denver, Colorado • Fort Lauderdale, Florida • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2015 · Synced Sep 11, 2026, 9:10 PM EDT
Completed Not applicable Interventional

Dexamethasone Infusion to the Adventitia to Enhance Clinical Efficacy After Femoropopliteal Revascularization

NCT01507558
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Administration of dexamethasone to SFA/popliteal adventitia
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2018 · Synced Sep 11, 2026, 9:10 PM EDT
Completed Phase 1 Interventional

Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL

NCT01333046
View directory record Official record
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions
Antigen-Escalation Stage, Dose-Escalation Stage, azacytidine and multiTAA T cells Stage, Pediatric multiTAA T cells Stage
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 11, 2026, 9:10 PM EDT
Completed Phase 1Phase 2 Interventional

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

NCT00782106
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Recombinant human hyaluronidase + immune globulin intravenous
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
16 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Centennial, Colorado • North Palm Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 11, 2026, 9:10 PM EDT